Robert W. Baird Reiterates “Sell” Rating for Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “sell” rating reaffirmed by investment analysts at Robert W. Baird in a research report issued on Friday. They presently have a $408.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price objective would suggest a potential downside of 13.47% from the stock’s current price.
Several other analysts have also issued reports on the company. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Vetr lowered Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 target price on the stock. in a report on Monday, May 15th. Piper Jaffray Companies upped their target price on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Finally, Leerink Swann reiterated an “outperform” rating and set a $493.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $496.35.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.09% on Friday, hitting $471.49. The stock had a trading volume of 761,263 shares. The firm’s 50 day moving average is $483.45 and its 200-day moving average is $442.76. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The stock has a market capitalization of $49.99 billion, a PE ratio of 47.30 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 29.95% and a net margin of 26.38%. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue was up 21.2% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/09/robert-w-baird-reiterates-sell-rating-for-regeneron-pharmaceuticals-inc-regn.html.
In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 663 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total transaction of $330,571.80. Following the completion of the sale, the senior vice president now directly owns 10,099 shares in the company, valued at $5,035,361.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael S. Aberman sold 2,269 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the sale, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold 129,257 shares of company stock worth $61,745,394 in the last three months. 10.40% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Henderson Group PLC lifted its stake in Regeneron Pharmaceuticals by 2.0% during the first quarter. Henderson Group PLC now owns 10,022 shares of the biopharmaceutical company’s stock worth $3,883,000 after purchasing an additional 200 shares during the last quarter. Comerica Bank lifted its stake in Regeneron Pharmaceuticals by 2.4% during the first quarter. Comerica Bank now owns 30,704 shares of the biopharmaceutical company’s stock worth $11,257,000 after purchasing an additional 714 shares during the last quarter. Xact Kapitalforvaltning AB lifted its stake in Regeneron Pharmaceuticals by 2.7% during the first quarter. Xact Kapitalforvaltning AB now owns 13,525 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 354 shares during the last quarter. Pictet Asset Management Ltd. lifted its stake in Regeneron Pharmaceuticals by 5.8% during the first quarter. Pictet Asset Management Ltd. now owns 330,319 shares of the biopharmaceutical company’s stock worth $128,002,000 after purchasing an additional 17,986 shares during the last quarter. Finally, LS Investment Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 12.4% during the first quarter. LS Investment Advisors LLC now owns 2,063 shares of the biopharmaceutical company’s stock worth $799,000 after purchasing an additional 228 shares during the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.